FDA Requires Vitamin B6 Deficiency Warning for Carbidopa/Levodopa

FDA says it is requiring application holders for all drug products containing carbidopa/levodopa to add a warning that these medicines can cause vitamin B6 deficiency and vitamin B6 deficiency-associated seizures. The agency says the products are approved to treat symptoms of Parkinson’s disease.

This is a useful reminder that postmarketing safety review can still materially change the labeling of long-established therapies. For pharmacovigilance teams, the key point is not only the warning itself, but the way ongoing surveillance continues to refine real-world monitoring expectations over time. That conclusion is an inference based on FDA’s requirement for new warning language.